Dr. Kinyas Hair Clinic · Science and Research Centre
Donor Miniaturisation: Why Examine the Back of the Scalp Separately?
Hair at the back and sides should not be considered unconditionally permanent simply because of its location. The distribution and cause of donor thinning may affect the reliability of the region chosen for transplantation.
Distinguishing naturally fine hair from miniaturisation
Naturally fine hair and hair becoming thinner through disease require different interpretation. Miniaturisation is assessed with clinical progression and regional features. A single shaft diameter or photograph cannot diagnose the entire donor area. [1], [2]
Density is another distinct measurement. Many fine hairs may provide different coverage from thicker hairs. Harvest planning should consider the quality of the hair left behind, as well as follicular-unit counts. [3]
Why a single point at the back may be insufficient
The lower and lateral scalp boundaries, central occipital region and other areas may differ. Some losses progress from the margins, whereas others are more diffuse. Mapping only an apparently strong point may conceal vulnerable areas. [1], [2]
Regional images should specify the measured field and counting definitions. A study’s normal average does not establish that an individual donor is safe. Assessment combines different regions with the patient’s history. [3]
Why clarify the diagnosis first?
Diffuse shedding, recession of the lower boundary, previous harvesting and other skin diseases can cause similar-looking thinning. They should not automatically be attributed to the same androgenetic process. Symptoms, examination and, when needed, further investigation matter. [1], [2]
Redness, marked scaling or loss of follicular openings may prompt broader assessment. Biopsy is selected according to the individual clinical question; there is no universal test list for everyone. This section describes the assessment sequence rather than making a diagnosis. [2]
Can one percentage determine the surgical decision?
A miniaturisation percentage is meaningful only with the classification method and sampling site. Measurements using different magnifications or definitions should not be conflated. This review did not verify a universal surgical exclusion threshold for all patient groups. [1], [2], [3]
If reassessment is needed, the same methods and sites are preferable. Improvement in a measurement with treatment does not prove lifelong reliability of the entire donor. Progression and remaining reserves require separate consideration before surgery. [1], [2] (clinical monitoring interpretation)
What should an individual plan explain?
Ask which donor regions appear more reliable and how uncertainty would change the target or timing. A total graft target alone does not explain donor biology. [1], [2] (consultation recommendation)
Options may include observation, medical assessment, a more limited target or declining surgery. This page does not suggest the same decision for everyone with donor thinning. The aim is to assess both the follicles harvested and the region left behind.
References and access limitations
This article is based on a targeted review of sources; it is not an original systematic review.
- ISHRS FUE Advancement Committee. FUE Clinical Practice Guidelines. 15 July 2019.
Professional expert guidance. It does not replace individual examination or establish a fixed safe percentage or total count.
- Mysore V et al. Hair Transplant Practice Guidelines. J Cutan Aesthet Surg. 2021;14:265–284. DOI: 10.4103/JCAS.JCAS_104_20.
Expert practice guidance. Includes expert opinion where evidence is lacking; not presented as Turkish legislation or a universal standard of care.
- Chang WC et al. Mapping the hair density, thickness, and volume in normal and androgenetic alopecia subjects with the digital microscope. JEADV Clin Pract. 2023;2:174–178. DOI: 10.1002/jvc2.86.
Observational cross-sectional measurement study. 160 participants: 49 normal and 111 with AGA; 80 men/80 women. Eleven regions, three images per region, three assessors. The accessible extended table is incomplete; not a safe surgical harvesting trial. Online December 2022; volume 2023.